Your browser doesn't support javascript.
loading
Toll-like receptor 8 agonist nanoparticles mimic immunomodulating effects of the live BCG vaccine and enhance neonatal innate and adaptive immune responses.
Dowling, David J; Scott, Evan A; Scheid, Annette; Bergelson, Ilana; Joshi, Sweta; Pietrasanta, Carlo; Brightman, Spencer; Sanchez-Schmitz, Guzman; Van Haren, Simon D; Ninkovic, Jana; Kats, Dina; Guiducci, Cristiana; de Titta, Alexandre; Bonner, Daniel K; Hirosue, Sachiko; Swartz, Melody A; Hubbell, Jeffrey A; Levy, Ofer.
Afiliación
  • Dowling DJ; Department of Medicine, Division of Infectious Diseases, Boston Children's Hospital, Boston, Mass; Harvard Medical School, Boston, Mass. Electronic address: david.dowling@childrens.harvard.edu.
  • Scott EA; Department of Biomedical Engineering, Northwestern University, Evanston, Ill. Electronic address: evan.scott@northwestern.edu.
  • Scheid A; Department of Medicine, Division of Infectious Diseases, Boston Children's Hospital, Boston, Mass; Harvard Medical School, Boston, Mass; Division of Newborn Medicine, Floating Hospital for Children, Tufts Medical Center, Boston, Mass; Precision Vaccine Program, Division of Infectious Diseases, Bosto
  • Bergelson I; Department of Medicine, Division of Infectious Diseases, Boston Children's Hospital, Boston, Mass.
  • Joshi S; Department of Medicine, Division of Infectious Diseases, Boston Children's Hospital, Boston, Mass; Precision Vaccine Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, Mass.
  • Pietrasanta C; Department of Medicine, Division of Infectious Diseases, Boston Children's Hospital, Boston, Mass; Harvard Medical School, Boston, Mass; Neonatal Intensive Care Unit, Department of Clinical Sciences and Community Health, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan,
  • Brightman S; Department of Medicine, Division of Infectious Diseases, Boston Children's Hospital, Boston, Mass; Precision Vaccine Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, Mass.
  • Sanchez-Schmitz G; Department of Medicine, Division of Infectious Diseases, Boston Children's Hospital, Boston, Mass; Harvard Medical School, Boston, Mass; Precision Vaccine Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, Mass.
  • Van Haren SD; Department of Medicine, Division of Infectious Diseases, Boston Children's Hospital, Boston, Mass; Harvard Medical School, Boston, Mass; Precision Vaccine Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, Mass.
  • Ninkovic J; Department of Medicine, Division of Infectious Diseases, Boston Children's Hospital, Boston, Mass; Harvard Medical School, Boston, Mass.
  • Kats D; Department of Biomedical Engineering, Northwestern University, Evanston, Ill.
  • Guiducci C; Dynavax Technologies, Berkeley, Calif.
  • de Titta A; Institute of Bioengineering, School of Life Sciences and School of Engineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
  • Bonner DK; Institute of Bioengineering, School of Life Sciences and School of Engineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
  • Hirosue S; Institute of Bioengineering, School of Life Sciences and School of Engineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
  • Swartz MA; Institute of Bioengineering, School of Life Sciences and School of Engineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland; Institute for Molecular Engineering, University of Chicago, Chicago, Ill.
  • Hubbell JA; Institute of Bioengineering, School of Life Sciences and School of Engineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland; Institute for Molecular Engineering, University of Chicago, Chicago, Ill.
  • Levy O; Department of Medicine, Division of Infectious Diseases, Boston Children's Hospital, Boston, Mass; Harvard Medical School, Boston, Mass; Precision Vaccine Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, Mass. Electronic address: ofer.levy@childrens.harvard.edu.
J Allergy Clin Immunol ; 140(5): 1339-1350, 2017 Nov.
Article en En | MEDLINE | ID: mdl-28343701
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Quinolinas / Células Dendríticas / Vacuna BCG / Monocitos / Adyuvantes Inmunológicos / Nanopartículas / Imidazoles Límite: Animals / Humans / Newborn Idioma: En Revista: J Allergy Clin Immunol Año: 2017 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Quinolinas / Células Dendríticas / Vacuna BCG / Monocitos / Adyuvantes Inmunológicos / Nanopartículas / Imidazoles Límite: Animals / Humans / Newborn Idioma: En Revista: J Allergy Clin Immunol Año: 2017 Tipo del documento: Article